loading page

AMBULATORY MICRO-DOSE INDUCTION OF BUPRENORPHINE-NALOXONE IN TWO ADOLESCENT PATIENTS WITH SICKLE CELL DISEASE
  • +1
  • Bradley Buchheit,
  • Timothy Joslin,
  • Helen Turner,
  • Trisha E. Wong
Bradley Buchheit
Oregon Health & Science University
Author Profile
Timothy Joslin
Oregon Health & Science University
Author Profile
Helen Turner
Oregon Health & Science University
Author Profile
Trisha E. Wong
Oregon Health & Science University
Author Profile

Abstract

Sickle cell disease (SCD) is a hematologic disorder defined by presence of sickle-shaped red blood cells that can occlude blood vessels and cause tissue ischemia and pain. Treating SCD pain adequately and safely is difficult given today’s opioid climate. Buprenorphine-naloxone is described in adult literature where it typically requires withdrawal of full-agonist opioids and inpatient hospitalization. Here we present two adolescents with SCD who successfully weaned off large doses of full-agonist opioids by using micro-dose induction of buprenorphine-naloxone in clinic. Ambulatory micro-dose induction may remove hurdles that otherwise would discourage patients from trying this regimen while still controlling pain safely.

Peer review status:UNDER REVIEW

08 Jun 2020Submitted to Pediatric Blood & Cancer
08 Jun 2020Submission Checks Completed
08 Jun 2020Assigned to Editor
15 Jun 2020Reviewer(s) Assigned
16 Jul 2020Review(s) Completed, Editorial Evaluation Pending
17 Jul 2020Editorial Decision: Revise Major
10 Aug 2020Assigned to Editor
10 Aug 20201st Revision Received
10 Aug 2020Submission Checks Completed
21 Aug 2020Reviewer(s) Assigned
30 Aug 2020Review(s) Completed, Editorial Evaluation Pending
31 Aug 2020Editorial Decision: Revise Minor
24 Sep 20202nd Revision Received
24 Sep 2020Submission Checks Completed
24 Sep 2020Assigned to Editor
25 Sep 2020Reviewer(s) Assigned